LONDON – GlaxoSmithKline PLC (GSK.LN) Wednesday said a Phase III study of its shingles vaccine Shingrix showed a strong immune response in older adults, meeting its primary objective.
Continue Reading Below
Shares at 1309GMT, down 13 pence, or 0.8%, at 1,680 pence valuing the company at GBP82.62 billion
-Write to Rory Gallivan at firstname.lastname@example.org; Twitter: @RoryGallivan
(END) Dow Jones Newswires
June 21, 2017 09:25 ET (13:25 GMT)